Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03630328 · ClinicalTrials.gov registry record · NA
Angelica Gigas Dietary Supplements and Human Immune Cells
A NA study of Innate Immune Cells, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03630328: Completed NA study of Innate Immune Cells, sponsored by Milton S. Hershey Medical Center.
NCT03630328 is a NA study of Innate Immune Cells that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03630328, a NA study of Innate Immune Cells, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. The investigators had done an earlier study with Korean Angelica supplement and discovered even a single dose of it increased blood neutrophils and NK cells within 24 h. In the new study, Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo) capsules. This is to make sure the immune boosting actions are really from the Korean Angelica supplement.
Primary Outcome
Using CBC diff to measure neutrophil counts, NK cells number will be enumerated using flowcytometer
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Cogni.Q
Study Locations (1)
Pennsylvania
- Penn State College of Medicine - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2026-02-25 |
| Phase | NA |
What the finished NCT03630328 record still lists
NCT03630328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Innate Immune Cells appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03630328 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03630328 about?
NCT03630328 is a clinical study titled "Angelica Gigas Dietary Supplements and Human Immune Cells". This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. The investigators had done an earlie...
What is the current status of trial NCT03630328?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2019-02-06. Estimated completion is 2026-02-25.
What conditions does trial NCT03630328 study?
This clinical trial studies the following conditions: Innate Immune Cells.
What interventions are being tested in trial NCT03630328?
The interventions under investigation include: Placebo (OTHER), Cogni.Q (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03630328?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03630328 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03630328's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI